Triptorelin.txt

CLINICAL USE

Advanced prostate cancer Endometriosis Precocious puberty Uterine fibroids prior to surgery

DOSE IN NORMAL RENAL FUNCTION

3–3.75 mg every 4 weeks; depends on preparation 11.25 mg every 3 months

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 1311.4

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : No data

%Excreted unchanged in urine &nbsp &nbsp : 3–14

Volume of distribution (L/kg) &nbsp &nbsp &nbsp : 92.4–115.8 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp : 7.5/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function, but monitor carefully

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function, but monitor carefully

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully

HDF/high flux &nbsp : Unknown dialysability. Dose as in normal renal function, but monitor carefully

CAV/VVHD &nbsp &nbsp &nbsp: Unlikely to be dialysed. Dose as in normal renal function, but monitor carefully

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

With 2 mL diluent provided

Route

SC, IM

Rate of Administration

–

Comments

– .

Tags: post-by-auto-php